# Bewegen bij coronairlijden een evidence based approach

T. Pustjens



#### Table I Continued

#### Components

- For secondary prevention in very-high-risk patients (i.e. documented ASCVD, either clinical or unequivocal on imaging), an LDL-C reduction of >50% from baseline and an LDL-C goal of <1.4 mmoVL (<55 mg/dL) are recommended</li>
- For patients with ASCVD who experience a second vascular event within 2two years (not necessarily of the same type as the first event) while taking
  maximally tolerated statin therapy, an LDL-C goal of <1.0 mmol/L (<40 mg/dL) may be considered</li>
- No goal for triglycerides, but <1.7 mmol/L (<150 mg/dL) indicates lower risk and higher levels indicate a need to look for other risk factors</li>
   Blood pressure management
- Assessment: BP frequently at rest. During exercise BP should be monitored when hypertension on effort is suspected. A SBP up to 200 mmHg at 100 W during exercise is advised as acceptable upper limit<sup>25</sup>
- Intervention:
- Offer lifestyle intervention in high-normal BP and grade 1-2-3 hypertension
- Consider drug treatment in high normal BP, in very high risk patients with CVD
- Drug treatment in grade 1–2–3 hypertension

#### Expected outcomes:

- BP <140/ 90 mmHg in all patients (targeted to 130/80 mmHg or lower in most patients when treatment is well tolerated)</li>
- SBP in the range 120–129 mmHg in most <65 years patients receiving BP-lowering drugs</li>
- SBP targeted to a range of 130–139 mmHg in older patients (aged ≥65 years) receiving BP-lowering drugs, with close monitoring of adverse effects
- DBP target of <80 mmHg for all hypertensive patients, independent of the level of risk and comorbidities.</li>

#### Smoking cessation

- All smokers should be professionally encouraged to permanently stop smoking all forms of tobacco. Follow-up, referral to special multidisciplinary
  programmes and/or pharmacotherapy (including nicotine replacement) are recommended, as a stepwise strategy for smoking cessation. Structured
  approaches are to be used, for example, 5As: Ask, Advise, Assess, Assist, Arrange
- Ask the patient about his/her smoking status and use of other tobacco products. Specify both amount of smoking (cigarettes per day) and duration
  of smoking (number of years)
- Determine readiness to change; if ready, choose a date for quitting
- Assess for PSRFs that may impede success
- Intervention: provide structured follow-up. Offer behavioural advice and group or individual counselling
- Offer nicotine replacement therapy and/or bupropion, varenicline
- Smokers who quit smoking during hospitalization should be strongly supported to stay smoke free using the above steps in smoking cessation
- Patients trying to quit smoking should be helped in maintaining weight during this period, since are more likely to put on between 3 and 5 kg in the first three months to a year
- Offer assistance to avoid passive smoking
- No role of e-cigarettes for smoking cessation (unclear evidence about whether e-cigarettes or other Electronic Nicotine Delivery Systems are useful and safe<sup>26</sup>)

#### Expected outcome:

Long-term abstinence from smoking

Psychosocial management

- Assessment for PSRFs: low socio-economic status, lack of social support, stress at work and in family life, posttraumatic stress, hostility, social isola tion, cognitive impairment, depression, anxiety and other mental disorders.
- Adoption of a two-step evaluation of PSRFs in CR: first, to ask the patient single-item questions about distinct PSRFs and then to apply standardized
  questionnaires (i.e. the HeartQoL for quality of life in patients with CHD across European language groups; or HADS for anxiety/depression)
- Intervention:
- Provide multimodal behavioural interventions, integrating health education, physical exercise and psychological therapy, for PSRFs and coping with illness
- Referral to psychiatrist for psychotherapy, medication or collaborative care should be considered in the case of clinically symptoms of depression, anxiety or hostility
- Whenever possible, induce spouses and other family members, domestic partners, and/or significant others in such sessions (to be applied to other lifestyle measures also). Teach and support self-help strategies and ability to obtain effective social support.
- Integrate systematically psychosocial management with sexual counselling when appropriate
- When appropriate, provide vocational reintegration/return to work strategies of patients after an acute cardiac event Expected outcome:

Absence of clinically significant psychosocial problems and acquisition of stress management skills. Work resumption and/or resumption of meaningful daily activities

#### Table I Continued

#### Components

al

#### Evaluation of the programme results and establishment of structured follow-up

Expected outcome:

coronary intervention

- Individual determination of success or failure for each area of intervention
- Establishment of new rehabilitative goals based on successful and unsuccessful areas of intervention
- Adequate transmission of information for continuing of care
- Quality assurance of intervention using systematic registration on individual level.
- Establishment of structured follow-up focused on rehabilitative goals and secondary prevention in the short and long term.

Table 2 Core components of cardiac rehabilitation post acute coronary syndrome and post primary percutaneous

Components	Established/agreed issues	Class (level)	Issues requiring further evidence
Patient	Clinical history: review clinical course of ACS and comorbidities	I (A)	
assessment	<ul> <li>Physical examination: inspect puncture site, search other vascular atherosclerot- ic localizations</li> </ul>		
	<ul> <li>Evaluation: clinical condition, medications, risk factors, psychological and social aspects, exercise capabilities</li> </ul>		
	<ul> <li>Peak exercise capacity evaluation before and after CR completion: symptom lim- ited exercise stress testing by bicycle ergometry or treadmill stress test (CPET recommended if available)</li> </ul>	1 (A)	Utility and feasibility of CPET in all CR patients
	<ul> <li>Assess myocardial ischaemia and viability by means of stress echo, CMR, SPECT, or PET, if not performed during acute hospital stay</li> </ul>	Ib (C)	
	<ul> <li>In patients with pre-discharge LVEF ≤40%, repeat echocardiography 6–12 weeks after MI, and after complete revascularization and optimal medical therapy, to as- sess the potential need for primary prevention ICD implantation and potential function accounts. Account is cited of with thering human interaction.</li> </ul>	I (C)	
Physical activity	function recovery. Assess the risk of arrhythmias by Holter-24 and exercise test If not otherwise specified according to individual clinical pattern, recommend	1 (A)	Safety of vigorous intensity
counselling	patients after the end of the CR programme to accumulate at least 30 min/day, 5 days/week of moderate intensity PA (i.e. 150 min/week) or 15 min/ day, 5 days/		and HIIT without supervision
	week of vigorous intensity PA (75 min/week), or a combination of both, per-		
	formed in sessions with a duration of at least 10 min. Shorter exercise sessions (i.e. <10 min) may also be appropriate, especially in very deconditioned individuals		
Exercise training	The programme should include supervised medically prescribed aerobic exercise	I (B)	<ul> <li>Modern definition of low</li> </ul>
-	training:		and moderate-to-high ri
	<ul> <li>Low-risk patients: see Table 1.</li> </ul>		patients
	<ul> <li>Moderate to high-risk patients because of left ventricular dysfunction, coron-</li> </ul>		<ul> <li>Utility and best protoco</li> </ul>
	ary disease severity, comorbidities, ageing: similar to low risk group but start- ing at 40% of the HRR		of aerobic HIIT
	<ul> <li>In case of asymptomatic ischemia consider 40–60% of heart rate reserve at the onset of ischaemia. Prophylactic nitroglycerine can be taken at the start of</li> </ul>		
	the training session in selected cases Resistance training to increase exercise capacity and muscle strength (see Toble 1)		
Lipid	After ACS if the LDL-C goal is not achieved after 4–6 weeks despite maximal toler-		
management	ated statin therapy and ezetimibe, addition of a PCSK9 inhibitor is recommended		

ACS: acute coronary syndrome: CMR: cardiac magnetic resonance; CPET: cardiopulmonary exercise testing: CR: cardiac rehabilitation; HIIT: high intensity interval training: HRR: heart rate reserve; ICD: implantable cardiac defibrillator; LDL-C: low-density lipoprotein cholesterol; LVEF: left ventricular ejection fraction; MI: myocardial infarction; PA: physical activity; PET: positron emission tomography; SPECT: single-photon emission computed tomography



### **Cardiac rehabilitation in coronary artery disease**


- Exercise-based training
  - Moderate vs. high-intensity training
- Resistance training
  - Resistance training + aerobic exercise vs aerobic exercise
- ESC guideline recommendations
- Challenges in cardiac rehabilitation
- Cost-effectiveness







### **General physical activity**



Leisure-time Physical Activity (MET-h/w

#### Conclusions

- Large reduction of all-cause mortality
- Modest amount of exercise is beneficial
- Large amount of exercise is not harmful



Arem. JAMA Intern Med. 2015 Kraus. Med Sci Sports Exerc. 2019




Gaesser. BMJ – Christmas special. 2022



#### **Exercise-based cardiac rehabilitation**







# Exercise-based cardiac rehabilitation for coronary heart disease (Review)


Dibben G, Faulkner J, Oldridge N, Rees K, Thompson DR, Zwisler AD, Taylor RS

- Cochrane review (2021)
  - 85 RCTs of exercise based interventions compared with 'no exercise'
  - Almost 25,000 patients with coronary heart disease
- Short-term FUP (6-12months)
  - All-cause mortality RR 0.87 [0.73-1.04]
  - Myocardial infarction RR 0.72 [0.55-0.93]
  - All-cause hospitalization RR 0.58 [0.43-0.77]
  - No difference in cardiovascular mortality, and revascularization procedures
- Medium-term FUP (12-36months)
  - Cardiovascular mortality RR 0.77 [0.63-0.93]
- Long-term FUP (>36 months)
  - Cardiovascular mortality RR 0.58 [0.43-0.78]
  - Myocardial infarction RR 0.67 [0.50-0.90]
- Improvement in QoL




#### Moderate vs. high-intensity training (HIT)

A. AIT programme (38 min)




(ACT)

B. ACT programme (47 min)



### **SAINTEX-CAD** study





Conraads. IJC. (2015).

## Moderate vs. high-intensity training (HIT)

• HIT

Key in exercise-based CR is the total energy expenditure rather than The specific training characteristic


- More time-efficient
- Adherence after termination of CR?
- Clinical relevance?





#### **Resistance training: does it matter?**

- Low muscular strength is a risk factor for all-cause and cardiovascular death
- Resistance training is associated with lower mortality






#### (d) Hazard ratio Hazard ratio Study or subgroup log[Hazard ratio] SE Weight IV, random, 95% CI IV, random, 95% CI -0.5014 0.3864 Courneya 2014 0.61 [0.28, 1.29] 5.6% Kamada 2017 -0.462 0.1605 20.2% 0.63 [0.46, 0.86] Loprinzi 2015 -1.0498 0.3684 6.1% 0.35 [0.17, 0.72] Schoenborn 2011-A -0.6162 0.0601 0.54 [0.48, 0.61] 37.9% -0.3147 0.1001 Schoenborn 2011-B 30.2% 0.73 [0.60, 0.89] Total (95% CI) 100.0% 0.60 [0.49, 0.72] Heterogeneity: Tau<sup>2</sup> = 0.02; Chi<sup>2</sup> = 8.83, df = 4 (P = 0.07); $I^2$ = 55% 00 0.01 **U**. I τU Test for overall effect: Z = 5.26 (P < 0.00001) Resistance + aerobic No exercise Test for overall effect: z = 3.31 (r = 0.0009) Resistance No exercise



## Resistance training: does it matter?



Naci. Br J Sports Med. 2019

#### **Resistance training in coronary artery disease**

- Resistance exercise; 2-3 times/week
  - Upper body: 8-10 repetitions of 30-70% of the 1 repetition maximum (1RM)
  - Lower body: 12-15 repetitions of 40-80% of 1RM



		Total		ontrol		d Moints	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl
				50	100	a vveigne	IV, Random, 95% CI	IV, Random, 95% CI
ax (K	I+AI	vs A	1)					
21.85		50		2.34	5	70		
						200 0.0017001		
1204.4								
		17						
			1.000000					
					- 13D			-
	0.000					70		
1000003		1.5						
1.000	1000					T		Ť
						T.)		
20.66	4.06			3.92				
S 23		383			38	1 87.7%	1.36 [0.40, 2.31]	· · · · ·
(P = 0	005)							
22.06	2.17	40	20.54	2.38	4	0 8.6%	1.52 [0.52, 2.52]	
18.2	5	19	19	6	1	9 3.7%		
		59			5	9 12.3%		*
$f^{p} = 1.5$	55, df =	= 1 (P =	0.21);	I <sup>#</sup> = 36	%			2022
(P = 0	30)							
		442	li nan		44	0 100.0%	1.26 [0.41, 2.12]	◆
(P = 0.	.004)	0.91502		anna an		570		
9 1.	4	54 3	25.7 1	.6	52	36.1%	0.20 [-0.37, 0.77]	•
5	6	16 2	22.1	4	16	28.4%	0.40 [-3.13, 3.93]	
6	4 1	00 1	15.3 3	7 1	00	35.\$%	5.30 [4.23, 6.37]	-
	1	70		1	68	100.0%	2.07 [-1.96, 6.09]	
	(P = 0, 22.06 18.2 (P = 0, (P = 0, Chi* = 3 1. 5 5 6	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	25.9       3       10       23.1       6       1         4.93       3.6       37       15.87       3.73       3         26.5       5.9       17       25.1       6.6       2         26.72       5.21       20       23.54       3.86       1         30.9       3.6       8       23.9       5.9       26.2       1.6       53       25.7       1.6       5         26.5       4.8       10       19.6       5.5       1       17.3       4.3       16       16       3.6       1         23.4       1.3       19       23.4       1.2       1       23.2       1.6       2.3       1.2       18       23.4       1.2       1         25.32       2.55       22       25.71       1.65       2       2.3.7       4.1       35       21.5       3.8       3         20.66       4.06       4.6       16.89       3.92       4       383       38       38       38         22.06       2.17       40       20.54       2.38       4       18.2       5       19       19       6       1         14       18.2	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$

#### **ry disease**

## 5 patients)

g (AT) vs AT, and RT vs AT
f-Life

Fan. Front. Cardiovasc. Med. 2021

	Experimental			Control			5	Std. Mean Difference	Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	
1 Physical score										
1.1 RT+AT vs AT										
C Hung 2004	6.3	0.6	9	5.8	1.1	9	4.7%	0.54 [-0.41, 1.48]		
H Dor-Haim 2018	50.55	4.36	14	36.98	7.48	15	4.8%	2.14 [1.20, 3.07]		
HM Arthur 2007	46.44	8.89	37	39.93	10.93	35	8.0%	0.65 [0.17, 1.12]		
LD Zhai 2018	71.95	11.98	20	73.16	12.77	19	6.8%	-0.10 [-0.72, 0.53]		
Q Liang 2020	91.94	12.63	40	83.35	11.24	40	8.2%	0.71 [0.26, 1.16]	· · · · ·	
RJ Wang 2013	12	2.3	36	8	2.1	36	7.4%	1.80 [1.24, 2.35]		
S Marzolini 2015	52.1	4.4	19	49	7.7	16	6.5%	0.49 [-0.18, 1.17]		
S Marzolini 2015(RT3+AT)	50.3	6.6	18	49	7.7	16	6.5%	0.18 [-0.50, 0.85]		
0 mai20inii 2013(((13.A))				70.00	14.85	46	8.5%	0.50 [0.09, 0.92]		
	80.22	16.52	46	12.20	14.00	40	0.0 /0			
XW Zheng 2019		16.52		77.69		13	5.7%	0.37 (-0.41, 1.14)		
XW Zheng 2019 Z Khalid 2019 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.26;	81.92 Chi <sup>2</sup> = 34	11.99	13 252	77.69	10.33	13 245			•	
XW Zheng 2019 Z Khalid 2019 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.26; Test for overall effect: Z = 3.0 1.2 RT vs AT	81.92 Chi <sup>2</sup> = 34	11.99	13 252	77.69	10.33	13 245	5.7%	0.37 [-0.41, 1.14] 0.71 [0.33, 1.08]	•	
XW Zheng 2019 Z Khalid 2019 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.26; Test for overall effect: Z = 3.0 1.2 RT vs AT S Ghroubi 2013 Y Du 2015 Subtotal (95% CI)	81.92 Chi <sup>2</sup> = 34 66 (P = 0 75 70.47	11.99 4.70, df 0.0003) 18 16.69	13 252 = 9 (P < 16 100 116	77.69 0.0001 65 69.95	10.33 ); I² = 74 30 17.53	13 245 4% 16 190	5.7% 67.1% 6.3%	0.37 [-0.41, 1.14] 0.71 [0.33, 1.08]	•	
XW Zheng 2019 Z Khalid 2019 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.26; Test for overall effect: Z = 3.0 <b>1.2 RT vs AT</b> S Ghroubi 2013 Y Du 2016 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Test for overall effect: Z = 1.3 <b>1.3 RT vs UC</b> HJ Jia 2018	81.92 Chi <sup>2</sup> = 34 66 (P = 0 75 70.47 Chi <sup>2</sup> = 0. 33 (P = 0 4.17	11.99 4.70, df 0.0003) 18 16.69 43, df = .18) 0.63	13 252 = 9 (P < 16 100 116 1 (P = 1 58	77.69 0.0001 65 69.95 0.51); I <sup>2</sup> 3.68	10.33 ); I² = 74 30 17.53	13 245 4% 16 100 116	5.7% 67.1% 6.3% 9.5% 15.8%	0.37 [-0.41, 1.14] 0.71 [0.33, 1.08] 0.39 [-0.31, 1.09] 0.14 [ 0.14, 0.42] 0.18 [-0.08, 0.43] 0.79 [0.41, 1.17]		
XW Zheng 2019 Z Khalid 2019 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.26; Test for overall effect: Z = 3.0 <b>1.2 RT vs AT</b> S Ghroubi 2013 Y Du 2015 Subtotal (95% CI) Heterogeneity: Tau <sup>2</sup> = 0.00; Test for overall effect: Z = 1.0 <b>1.3 RT vs UC</b>	81.92 Chi <sup>2</sup> = 34 66 (P = 0 75 70.47 Chi <sup>2</sup> = 0. 33 (P = 0	11.99 4.70, df 0.0003) 18 16.69 43, df = .18) 0.63	13 252 = 9 (P < 16 100 116 1 (P = 1 58	77.69 0.0001 65 <del>60.05</del> 0.51); I <sup>2</sup>	10.33 ); I <sup>2</sup> = 74 30 17.53 = 0%	13 245 4% 16 199 116	5.7% 67.1% 6.3% 9.5% 15.8%	0.37 [-0.41, 1.14] 0.71 [0.33, 1.08] 0.39 [-0.31, 1.09] 0.14 [ 0.14, 0.42] 0.18 [-0.08, 0.43]		



### **Summary**

- Cardiac rehabilitation
  - ▼ Reduction in all-cause and cardiovascular mortality
  - ▼ Reduction in recurrent hospital admissions
  - ▲ Improves exercise capacity
  - ▲ Improves quality-of-life
- Exercise-based CR
  - Key is the total energy expenditure and not the type of exercise
- Resistance training
  - ▼ Reduces all-cause mortality
  - ▼ Reduces systolic blood pressure
  - ▲ Improvement of VO2 and QoL in CR



#### **ESC guideline recommendations**





### Cardiac rehabilitation in coronary heart disease

Indications CR referral

- Acute coronary syndromes
- Undergoing reperfusion
- Chronic coronary syndromes

Key components of CR

- Screening cardiovascular risk factors
- Physical activity counselling
- Exercise training
- Diet/nutritional counselling
- Risk factor control
  - LDL < 1.4mmol/L
  - BMI 18.5-25kg/m2
  - Blood pressure < 140/90mmHg
- Patient education
- Psychosocial management



## Physical activity

4.3.1. Physical activity and exercise

#### **Recommendations for physical activity**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
It is recommended for adults of all ages to strive for at least 150 - 300 min a week of moderate-		
intensity or 75 - 150 min a week of vigorous- intensity aerobic PA, or an equivalent combina- tion thereof, to reduce all-cause mortality, CV mortality, and morbidity. <sup>371,372</sup>	1	A
It is recommended that adults who cannot per- form 150 min of moderate-intensity PA a week should stay as active as their abilities and health condition allow. <sup>373,374</sup>	i.	в
It is recommended to reduce sedentary time to engage in at least light activity throughout the day to reduce all-cause and CV mortality and morbidity. <sup>375-377</sup>	I.	в
Performing resistance exercise, in addition to aerobic activity, is recommended on 2 or more days per week to reduce all-cause mortality. <sup>378,379</sup>	I	в

Visseren Eur Heart J (2021).


### Cardiac rehabilitation

#### **Recommendations for cardiac rehabilitation**

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
Participation in a medically supervised, struc- tured, comprehensive, multidisciplinary EBCR and prevention programme for patients after ASCVD events and/or revascularization, and for	I.	A
patients with HF (mainly HFrEF), is recom- mended to improve patient outcomes. <sup>638–642</sup>		
Methods to increase CR and prevention referral		
and uptake should be considered (i.e. electronic	lla	
prompts or automatic referrals, referral and liai-		в
son visits, structured follow-up by nurses or		
health professionals, and early programme initia- tion after discharge). <sup>643–646</sup>		
Home-based CR, telehealth, and mHealth inter-		
ventions may be considered to increase patient	ПР	в
participation and long-term adherence to		
healthy behaviours. <sup>647,648</sup>		




### **Challenges in cardiac rehabilitation**





OCRE 2.0. ESCardio.org



8 countries: mandatory 13 countries: non-existent 21 countries: optional



### **Remote cardiac rehabilitation programme**

#### **Rehab+ programme**

- Prospective, observational, control-matched trial
- Study sample 900 ACS patients
- 1:2 mobile telemonitoring vs regular programme
- Primary endpoint: QoL at 1 year measured by the SF-36 questionnaire
- Actual inclusions: >200



#### **Cost-effectiveness**





# Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000–2010

D. FIDAN<sup>1\*</sup>, B. UNAL<sup>1,2</sup>, J. CRITCHLEY<sup>3</sup> and S. CAPEWELL<sup>1</sup>

Costs per life-year gained (LYG)	
Aspirin and beta-blockers (secondary prev)	<£1000
ACE-inhibitor	£3398
Statins (primary prev)	£14557
Statins (secondary prev)	£4246
Primary angioplasty for myocardial infarction	£6054
Angioplasty (elective)	£3845
CABG	£3239
Cardiac rehabilitation	£1957



Fidan. Q J Med. 2007

### **Cost-effectiveness of CR**

- 2018 systematic review including 19 economic studies regarding CR
- Cost conversion to 2016 US Dollar
- General CR vs no CR
  - Positive net cost, but all showed an increase in health
  - Incremental cost-effectiveness ratio range from USD 1065 71755 per QALY
  - Exercise-based CR vs no CR was most cost-effective;
    - USD 1065 per QALY,
    - USD 2555-3367 per LYG







M.D.

DISPENSE AS WRITTEN

#### Literature

